Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Extension Study of ABT-122 in Rheumatoid Arthritis (M12-963 OLE)
2014-001471-31Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2015
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of remtolumab in rheumatoid arthritis (RA), sponsored by AbbVie Inc. Primary endpoint: Long-term safety and tolerability of ABT-122. Started Jan 2015; status: completed.
02
Drugs
remtolumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2014-001471-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001471-31.